SINGAPORE, Feb. 17, 2026 — Immortal Dragons, a longevity fund based in Singapore, has announced its additional support for 3D biofabrication as a key technical solution for age-related organ failure. This move indicates a change in the biotechnology investment landscape towards regenerative “replacement” models aimed at intervening before the start of chronic disease.
The Catalyst: 3D Biofabrication
In a recent technical discussion on the Inside Precision Medicine podcast, Boyang Wang, the founder of Immortal Dragons, elaborated on the firm’s focus on 3D biofabrication. This technology uses “bio-inks” – living cells combined with biocompatible materials – to create functional tissue.
The sector currently targets the $12 billion vascular graft market, where traditional synthetic solutions currently have failure rates of up to 65%. Recent large animal studies have shown that tissue-engineered blood vessels can achieve zero thrombosis and full tissue incorporation, significantly outperforming current synthetic standards.
Immortal Dragons’ support for Frontier Bio aligns with broader industry trends; in 2024, United Therapeutics received FDA clearance for the first human trial of a bioengineered organ. While full organ replacement is still in development, the clinical application of functional blood vessels shows that the technology is moving from laboratory research to medical practice.
The Four Pillars of the Future
The investment strategy of Immortal Dragons is influenced by the transition from traditional technology sectors to long-term biotechnological development. The firm operates on the assumption that solving age-related biological decline requires a multi-disciplinary framework.
According to Wang, the progress of the field depends on four distinct pillars:
- Science: Advancing the fundamental cellular understanding of aging.
- Capital: Implementing funding models that prioritize long-term clinical development over short-term exits.
- Policy: Modernizing regulatory frameworks to better evaluate preventative therapies.
- Ideology: Shifting public and professional discourse to treat aging as a manageable biological process.
A Coordinated Leap Forward
Recent developments highlight an industry-wide effort to integrate longevity research into mainstream biomedical science. While the extent of human healthspan extension remains a scientific question, the field is increasingly characterized by interdisciplinary coordination. The current goal for firms like Immortal Dragons is to establish rigorous, verifiable frameworks for evaluating these interventions through synchronized investment and regulatory oversight.
About Immortal Dragons
is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond traditional investments, the fund promotes longevity advocacy through book translation and publishing, translation of longevity leaders’ talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.
CONTACT: Media Contact Information Boyang Wang press@id.life
